{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:52:56Z","timestamp":1761519176026},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10637-016-0403-2","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T05:00:02Z","timestamp":1478581202000},"page":"87-94","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Murtuza","family":"Rampurwala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari B.","family":"Wisinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Ehsani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M.","family":"O\u2019Regan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakeesha","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amye J.","family":"Tevaarwerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"403_CR1","doi-asserted-by":"crossref","unstructured":"Stewart B, Wild C (2014) World Cancer Report","DOI":"10.12968\/nuwa.2014.10.2.1142051"},{"key":"403_CR2","unstructured":"American Cancer Society (2015) Cancer Facts & Figures. In."},{"key":"403_CR3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.1992.10.8.1284","volume":"10","author":"PM Ravdin","year":"1992","unstructured":"Ravdin PM, Green S, Dorr TM et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study. J Clin Oncol Off J Am Soc Clin Oncol 10:1284\u20131291","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"403_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529","journal-title":"N Engl J Med"},{"key":"403_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25\u201335","journal-title":"Lancet Oncol"},{"key":"403_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/0959-8049(96)00112-8","volume":"32A","author":"V Kuenen-Boumeester","year":"1996","unstructured":"Kuenen-Boumeester V, Van der Kwast TH, Claassen CC et al (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560\u20131565","journal-title":"Eur J Cancer"},{"key":"403_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cncr.11532","volume":"98","author":"F Moinfar","year":"2003","unstructured":"Moinfar F, Okcu M, Tsybrovskyy O et al (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98:703\u2013711","journal-title":"Cancer"},{"key":"403_CR8","doi-asserted-by":"publisher","first-page":"djt319","DOI":"10.1093\/jnci\/djt319","volume":"106","author":"FE Vera-Badillo","year":"2014","unstructured":"Vera-Badillo FE, Templeton AJ, de Gouveia P et al (2014) Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 106:djt319","journal-title":"J Natl Cancer Inst"},{"key":"403_CR9","first-page":"1447","volume":"39","author":"JC Allegra","year":"1979","unstructured":"Allegra JC, Lippman ME, Thompson EB et al (1979) Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39:1447\u20131454","journal-title":"Cancer Res"},{"key":"403_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","volume":"121","author":"F De Amicis","year":"2010","unstructured":"De Amicis F, Thirugnansampanthan J, Cui Y et al (2010) Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121:1\u201311","journal-title":"Breast Cancer Res Treat"},{"key":"403_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-008-9923-6","volume":"112","author":"DM Harvell","year":"2008","unstructured":"Harvell DM, Richer JK, Singh M et al (2008) Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat 112:489\u2013501","journal-title":"Breast Cancer Res Treat"},{"key":"403_CR12","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.2006.09.0118","volume":"25","author":"A Micheli","year":"2007","unstructured":"Micheli A, Meneghini E, Secreto G et al (2007) Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 25:2685\u20132690","journal-title":"J Clin Oncol"},{"key":"403_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-011-1611-2","volume":"130","author":"L Gallicchio","year":"2011","unstructured":"Gallicchio L, Macdonald R, Wood B et al (2011) Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 130:569\u2013577","journal-title":"Breast Cancer Res Treat"},{"key":"403_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1067\/msy.2001.118378","volume":"130","author":"KT Morris","year":"2001","unstructured":"Morris KT, Toth-Fejel S, Schmidt J et al (2001) High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery 130:947\u2013953","journal-title":"Surgery"},{"key":"403_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Jones R, Oudard S et al (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 33:723\u2013731","journal-title":"J Clin Oncol"},{"key":"403_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","volume":"16","author":"F Saad","year":"2015","unstructured":"Saad F, Fizazi K, Jinga V et al (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 16:338\u2013348","journal-title":"Lancet Oncol"},{"key":"403_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-13-2436","volume":"20","author":"R Dreicer","year":"2014","unstructured":"Dreicer R, MacLean D, Suri A et al (2014) Phase I\/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 20:1335\u20131344","journal-title":"Clin Cancer Res"},{"key":"403_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"403_CR19","unstructured":"Institute NC (2009) Common terminology criteria for adverse events v4.0. In"},{"key":"403_CR20","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/bcr3599","volume":"16","author":"DR Cochrane","year":"2014","unstructured":"Cochrane DR, Bernales S, Jacobsen BM et al (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 16:R7","journal-title":"Breast Cancer Res"},{"key":"403_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jsbmb.2007.05.024","volume":"106","author":"H Anderson","year":"2007","unstructured":"Anderson H, Bulun S, Smith I, Dowsett M (2007) Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106:49\u201354","journal-title":"J Steroid Biochem Mol Biol"},{"key":"403_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/annonc\/mdp510","volume":"21","author":"S Park","year":"2010","unstructured":"Park S, Koo J, Park HS et al (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol 21:488\u2013492","journal-title":"Ann Oncol"},{"key":"403_CR23","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/1078-0432.CCR-10-2021","volume":"17","author":"R Hu","year":"2011","unstructured":"Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17:1867\u20131874","journal-title":"Clin Cancer Res"},{"key":"403_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/annonc\/mdv487","volume":"27","author":"J O\u2019Shaughnessy","year":"2016","unstructured":"O\u2019Shaughnessy J, Campone M, Brain E et al (2016) Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol 27:106\u2013113","journal-title":"Ann Oncol"},{"key":"403_CR25","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1200\/JCO.2013.49.4757","volume":"32","author":"D Yardley","year":"2014","unstructured":"Yardley D, Awada A, Cortes J (2014) A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer. J Clin Oncol 32:5s, (suppl; abstr TPS653). NCT02007512","journal-title":"J Clin Oncol"},{"key":"403_CR26","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1200\/JCO.2013.49.4757","volume":"32","author":"W Li","year":"2014","unstructured":"Li W, O\u2019Shaughnessy J, Ricci D (2014) Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI). J Clin Oncol 32:5s, suppl; abstr 520","journal-title":"J Clin Oncol"},{"key":"403_CR27","first-page":"2089","volume":"4","author":"J Geisler","year":"1998","unstructured":"Geisler J, King N, Anker G et al (1998) In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089\u20132093","journal-title":"Clin Cancer Res"},{"key":"403_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.20.3.751","volume":"20","author":"J Geisler","year":"2002","unstructured":"Geisler J, Haynes B, Anker G et al (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751\u2013757","journal-title":"J Clin Oncol"},{"key":"403_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/978-0-387-78818-0_7","volume":"630","author":"CA Lange","year":"2008","unstructured":"Lange CA, Sartorius CA, Abdel-Hafiz H et al (2008) Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol 630:94\u2013111","journal-title":"Adv Exp Med Biol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0403-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:01:35Z","timestamp":1678510895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0403-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0403-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]},"assertion":[{"value":"29 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Murtuza Rampurwala declares that he has no conflict of interest.Kari B Wisinski declares that she has no conflict of interest.Mark E Burkard declares that he has no conflict of interest.Sima Ehsani declares that she has no conflict of interest.Ruth M O\u2019Regan declares that she has no conflict of interest.Lakeesha Carmichael declares that she has no conflict of interest.KyungMann Kim declares that he has no conflict of interest.Jill Kolesar declares that she has no conflict of interest.Amye J Tevaarwerk declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by Millennium Pharmaceuticals. This work was supported by the NCI Cancer Center Support Grant P30 CA014520 and NCI U01CA062491 Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis. AJT and MEB have received support from the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grants UL1TR000427and KL2TR000428, while MR has received support from T32 CA009614.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}